BOSTON, Nov. 8, 2016 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present at the Stifel 2016 Healthcare Conference at 8:45 a.m. ET on Tuesday, November 15, 2016 in New York City.
Stealth BioTherapeutics: Leading Mitochondrial Medicine
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondrial therapies to patients to treat both rare diseases and common diseases of aging. Stealth's clinical development program is focused along several core therapeutic areas, including primary mitochondrial diseases, cardiorenal diseases and ophthalmic disorders. More information regarding Stealth and its pipeline is available at StealthBT.com.
Contact:
Media Relations
dna Communications
Kate Contreras
Phone: 617-520-7088
Media@StealthBT.com
Investor Relations
Stern IR
Beth DelGiacco
Phone: 212-362-1200
IR@StealthBT.com
SOURCE Stealth BioTherapeutics